Connect with us

Technology

Nigerian Communications Commission (NCC) Approves Airtel’s 900MHz and 1800MHz Spectrum Licences for 10 Years

Published

on

airtel

Nigerian Communications Commission (NCC) Approves Airtel’s 900MHz and 1800MHz Spectrum Licences for 10 Years

Africa’s leading telecommunications company, Airtel Africa, announced that the Nigerian Communications Commission (NCC) has approved its application for renewal of the spectrum licences in the 900MHz and 1800MHz bands.

Airtel Africa’s Nigerian subsidiary, Airtel Networks Limited (“Airtel Nigeria”) “has been approved by the Nigerian Communications Commission (NCC). These spectrum licences were otherwise due to expire on 30
November 2021,” the company stated.

It company further stated that after the successful application, the commission then offered the telecommunications giant the opportunity to renew its spectrum licences in the 900MHz and 1800MHz bands for a period of ten years with effect from 1 December 2021 until 30 November 2031, which Airtel Nigeria has accepted.

Airtel Nigeria added that under the agreed terms of the spectrum licences, it paid 71.611 billion Naira ($189 million) as licence renewal fees.

Commenting on the renewal, Raghunath Mandava, CEO of Airtel Africa, said: “I am pleased to announce that our application in Nigeria to renew our spectrum licences in the 900MHz and 1800MHz bands for a ten-year period has been approved by the NCC.”

“This is our largest market and we remain focused on bridging the digital divide and expanding our broadband capability in the country. On behalf of Airtel Nigeria and the Group, I would like to thank both the government of Nigeria and the NCC for their cooperation and support in this important process.

CEO/Founder Investors King Ltd, a foreign exchange research analyst, contributing author on New York-based Talk Markets and Investing.com, with over a decade experience in the global financial markets.

Technology

Fintech CEO: Morocco’s Move to Revisit CBDC Has Global Implications

Published

on

fintech

Scottsdale, Ari. – February 25, 2021 – Earlier this week, it was reported by both the Morocco World News and NASDAQ that Bank-Al-Maghrib, Morocco’s Central Bank, is forming an exploratory committee to deliberate whether the institution should launch a central bank digital currency. Significantly, only four years ago, the country banned cryptocurrencies.

“It isn’t so significant that yet another country is exploring the benefits of a CBDC, but, rather, the significance is in which country is doing the exploration,” explained Richard Gardner, CEO of Modulus, a US-based developer of ultra-high-performance trading and surveillance technology that powers global equities, derivatives, and digital asset exchanges. “Even the slightest consideration from Bank-Al-Maghrib marks a historic day for digital assets.”

The newly formed committee is said to be tasked with identifying the pros and cons, while remaining cautious due to the “speculative nature” of cryptocurrencies. This is in line with the country’s original critique that a lack of regulation created risk for consumers and investors.

“It’s worth noting that, despite the ban, Moroccans account for the fourth highest volume of trading in Bitcoin within the African continent, behind Kenya, Nigeria, and South Africa,” said Gardner. “A lot has changed in four years. A lot of bureaucrats were leery about the lack of regulatory oversight back then. Even now, many are still cautious. But, the power of cryptocurrencies is real, and they’re here to stay. Especially in Africa, digital currencies could radically change the lives of the unbanked. The fact that Bank-Al-Maghrib is even contemplating the benefits of digital assets — that’s something the whole world will be watching.”

Modulus is known throughout the financial technology segment as a leader in the development of ultra-high frequency trading systems and blockchain technologies. Over the past twenty years, the company has built a client list which includes NASDAQ, Goldman Sachs, Merrill Lynch, JP Morgan Chase, Bank of America, Barclays, Siemens, Shell, Yahoo!, Microsoft, Cornell University, and the University of Chicago.

“In addition to the raw power of digital currencies, the technology that powers blockchain-based solutions is something that region can’t afford to miss out on,” opined Gardner. “For example, blockchain-based authentication, especially when blended with artificial intelligence technologies, could be a gamechanger in authenticating malaria treatments. Using blockchain verification solutions, African governments could nearly eliminate counterfeit pharmaceuticals, which is a topic our company intends to continue to explore over the coming months and years.”

Continue Reading

Technology

Biotech Firm Launches Lassa Vaccine Trial in West Africa

Published

on

Lassa Fever

Biotech Firm Launches Lassa Vaccine Trial in West Africa

A biotechnology company, INOVIO, says the first participant in Lassa vaccine trial has been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever.

The clinical trial is being done in Ghana, the firm says, adding that INOVIO is focused on bringing to market precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer.

The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa Fever to be conducted in West Africa, where the infection is endemic.

The lead clinical Principal Investigator for LSV-002 is Professor Dr. Kwadwo A. Koram, an expert and specialist in tropical medicines and epidemiologist with more than 20 years of research experience, including malaria vaccines.

INO-4500 was also the first vaccine candidate for Lassa fever to enter human trials, PUNCH Healthwise reports.

Already, the Director-General of the Nigeria Centre for Disease Control, Dr. Chikwe Ihekweazu, has tweeted his commendation.

Said Ihekweazu, “Fantastic news. The urgency of now. A vaccine for Lassa fever. We have worked very hard with WHO, CEPI vaccines, ACEGID, BNITM_de and many others to put this on the global health agenda. We will keep pushing.”

According to a press release by the biotechnology company, INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership that leverages funding from public, private, philanthropic and civil society organisations to support research projects to develop vaccines against emerging infectious diseases.

INOVIO previously received a $56m grant from CEPI in 2018, under which the company is developing vaccine candidates for Lassa Fever and Middle East Respiratory Syndrome (MERS).

“INOVIO and CEPI are committed to making a vaccine available as soon as possible for emergency use as a stockpile product post-Phase 2 testing,” the press release stated.

The statement notes that INOVIO’s Phase 1B clinical trial, LSV-002, will enroll approximately 220 adult participants who are 18 – 50 years old, with the primary endpoints of evaluating safety and immunogenicity in an African population.

The dosing regimen involves two vaccinations at zero and 28 days with either 1.0 mg or 2.0 mg dosing levels. In addition to providing valuable insights on the INO-4500 safety and immunogenicity profile, this trial will inform dose selection for subsequent Phase 2 studies in West Africa.

Lassa fever is an animal-borne, acute hemorrhagic viral illness primarily observed in parts of West Africa.

Infection is spread through contact with infected rodents, as well as person-to-person transmission via bodily fluids (primarily in health care settings).

The disease can cause a range of outcomes, including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose and death.

Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, and is responsible for 10 – 16 percent of hospital admissions in the region. The virus is responsible for approximately 5,000 deaths annually.

Because of difficulties in diagnosing Lassa fever, the lack of standardised surveillance assays, and the remote nature of many of the areas in West Africa where outbreaks typically occur, the numbers of reported cases and deaths are very likely significantly lower than the actual numbers of cases and deaths.

Though the majority (about 80 percent) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. The case-fatality among patients hospitalized for Lassa fever is about 15 – 20 percent and, in some epidemics, case-fatality has reached 50 percent in hospitalized patients.

Up until now, there are no licensed vaccines or treatments specifically for Lassa fever.

Continue Reading

Technology

Google Says It Will Start Accepting Political Ads in US

Published

on

A logo is pictured at Google's European Engineering Center in Zurich

Google Says It Will Start Accepting Political Ads in US

Google has said it will resume accepting all political advertisements in the United States from Feb. 24.

The search giant disclosed in an email to advertisers on Monday.

Google paused all political advertisements in January when Trump’s mobs invaded U.S. Capitol.

Continue Reading

Trending